Work

Abstract PS1-08-05: First disclosure of efficacy and safety data for YL202/BNT326 (HER3 antibody-drug conjugate [ADC]) in advanced or metastatic HR+/HER2 null and HER2-low breast cancer: Phase 2 trial results

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps1-08-05

Authors: J. Zhang, Y. Meng, L. Cai, T. Wu, T. Sun, H. Li, Q. Ouyang, F. Xu, C. Trück, M. Wenger, R. Tibes, N. Wang, J. Bai, S. Chin

Institutions: Shanghai Medical College of Fudan University, Fudan University, Fudan University Shanghai Cancer Center, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Central South University, Liaoning Cancer Hospital & Institute, China Medical University, Shandong Tumor Hospital, Shandong First Medical University, Hunan Cancer Hospital, Sun Yat-sen University Cancer Center, BioNTech (Germany), MediLink Therapeutics (Suzhou) Co., Ltd. (China)

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129722225

Cites:

Cited by:

Related to: